tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

3 Best Stocks to Buy Now, 9/17/2025, According to Top Analysts

3 Best Stocks to Buy Now, 9/17/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and has a significant upside as well. 

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts. 

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

Ryan Specialty Group (RYAN) – Ryan Specialty is a provider of specialty insurance products and services for brokers, agents, and carriers. Today, Bernstein analyst Stacy Rasgon upgraded the rating on the stock to Buy from Neutral and maintained a price target of $60 per share. He believes that the stock’s pullback makes the valuation reasonable while its organic growth and margins should continue to beat peers. Interestingly, six out of the eight Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 40.71%.

Coca-Cola (KO) – Coca-Cola is a global beverage company best known for its soft drinks, juices, and bottled water brands. Today, RBC Capital analyst James Edwardes Jones maintained a Buy rating on the stock with a price target of $76 per share. In the last three months, all three Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 21.78%.

Dianthus Therapeutics (DNTH) – Dianthus Therapeutics is a clinical-stage biotech company developing antibody therapies for rare and severe autoimmune diseases. Yesterday, Clear Street analyst William Maughan maintained a Buy rating on the stock with a price target of $100 per share. In the last three months, all 13 Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 71.68%.

Who Are the Top Analysts? 

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time. 

See real-time analyst rankings and learn more about the performance of Top Analysts on TipRanks’ Top Wall Street Analysts page. 

Disclaimer & DisclosureReport an Issue

1